Status:
COMPLETED
A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Non-Small-Cell Lung Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to find a safe and effective dose of Erbitux and Iressa for subject with non small cell lung cancer.
Eligibility Criteria
Inclusion
- Subjects with advanced or metastatic non small cell lung cancer.
- Subjects should have had at least one prior chemotherapy with a platinum based therapy.
Exclusion
- Subjects are excluded from this study if they do not have non small cell lung cancer that is advanced or metastatic or have not had at least one prior platinum based chemotherapy.
Key Trial Info
Start Date :
March 1 2005
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00162318
Start Date
March 1 2005
End Date
April 1 2006
Last Update
October 28 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Pittsburgh, Pennsylvania, United States